NasdaqGM - Nasdaq Real Time Price USD

Atai Life Sciences N.V. (ATAI)

Compare
1.1700 -0.0200 (-1.68%)
At close: September 27 at 4:00 PM EDT
1.1703 +0.00 (+0.03%)
After hours: September 27 at 6:48 PM EDT
Loading Chart for ATAI
DELL
  • Previous Close 1.1900
  • Open 1.2000
  • Bid 1.1600 x 200
  • Ask 1.1900 x 400
  • Day's Range 1.1700 - 1.2000
  • 52 Week Range 1.0250 - 2.8500
  • Volume 639,452
  • Avg. Volume 592,990
  • Market Cap (intraday) 196.325M
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3600
  • Earnings Date Nov 5, 2024 - Nov 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.60

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

www.atai.life

83

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ATAI

View More

Performance Overview: ATAI

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ATAI
17.02%
S&P 500
20.30%

1-Year Return

ATAI
7.87%
S&P 500
34.27%

3-Year Return

ATAI
92.69%
S&P 500
28.79%

5-Year Return

ATAI
94.43%
S&P 500
37.72%

Compare To: ATAI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ATAI

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    196.32M

  • Enterprise Value

    127.61M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    497.59

  • Price/Book (mrq)

    1.17

  • Enterprise Value/Revenue

    337.59

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.97%

  • Return on Equity (ttm)

    -31.51%

  • Revenue (ttm)

    378k

  • Net Income Avi to Common (ttm)

    -58.07M

  • Diluted EPS (ttm)

    -0.3600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    88.35M

  • Total Debt/Equity (mrq)

    13.01%

  • Levered Free Cash Flow (ttm)

    -53.53M

Research Analysis: ATAI

View More

Company Insights: ATAI

Research Reports: ATAI

View More

People Also Watch